Testing a new drug duo for Tough-to-Treat colon cancer
NCT ID NCT00989469
Summary
This study tested whether adding the drug sorafenib to standard chemotherapy (irinotecan) could help control advanced colorectal cancer that had stopped responding to prior treatments. It involved 64 patients whose cancer had a specific genetic change (K-RAS mutation) and had spread. The main goals were to see if the combination could stop the cancer from growing and to check how safe it was for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Robert Debre
Reims, France
-
Centre Antoine Lacassagne
Nice, France
-
Centre Oscar Lambret
Lille, France
-
Centre Rene Gauducheau
Nantes, France
-
Hopital Saint Eloi
Montpellier, France
Conditions
Explore the condition pages connected to this study.